Nvidia earnings are set to rebound while AI leadership has excited investors in the leading chip stock. Nvidia stock is on a tear. Read More...
Pfizer Earnings Will Show How Much Covid Is Still Driving Revenue
As Pfize r reports its first quarter financial results on Tuesday morning, the company is looking to shift investor attention to the future: The recent approval of its new pneumococcal vaccine for children, the expected launch this year of its respiratory syncytial virus vaccine, a new treatment for alopecia areata that could hit the market later this year. On Sunday, the Financial Times reported that Pfizer (ticker: PFE) and its partner BioNTech (BNTX) are negotiating a deal to provide 70 million Covid-19 vaccine doses a year to the European Union through 2026. At its last earnings presentation in late January, Pfizer told investors to expect $13.5 billion of Covid-19 vaccine sales in 2023, down from $37.8 billion in 2022.